An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)

An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00449111

Enrollment

Registered

2007-03-19

Start date

2006-03-13

Completion date

2006-09-30

Last updated

2024-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

Evaluate blood pressure after 6 weeks of treatment with COZAAR plus.

Interventions

DRUGMK0954, losartan potassium / Duration of Treatment - 12 weeks

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient treated with valsartan 80mg or irbesartan 150mg or vandesartan 8mg for at least 4 weeks prior to visit 1 * Patient with systolic blood pressure between 140 to 159 mmhg and diastolic pressure between 90 to 99mmhg taken at visit 1

Exclusion criteria

* History of angina pectoris that has not been stabilized in the past 6 weeks * History of clinically significant abnormal lab results or diseases * Myocardial infarction within the past 6 months * Stroke in the past 6 months

Design outcomes

Primary

Measure	Time frame
Change of diastolic blood pressure after 6 weeks of treatment with cozaar plus	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026